'Former Ranbaxy shareholders hid key info on US investigation'

The Japanese drug maker added that it continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations.

Ranbaxy 'systematically violated' good manufacturing practices: whistleblower

The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas in India and included acne drug Sotret, epilepsy and nerve pain drug gabapentin and antibiotic ciprofloxacin.

Ranbaxy pleads guilty in US, to pay $500 mn in settlement

"Ranbaxy also agreed to pay a criminal fine and forfeiture totalling USD 150 million and to settle civil claims under the False Claims Act and related State laws for USD 350 million."